Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 15, 2007 Ryan Fuhrmann	LabCorp Takes Names Things are going well at LabCorp, but not so well at Quest Diagnostics. Still, the long-term attractiveness of the lab testing industry is favorable as the industry consolidates and demographics support increasing healthcare services.
The Motley Fool July 24, 2006 Ryan Fuhrmann	The Quest for Market Share Quest Diagnostics' second-quarter earnings mostly meet expectations. What might the future hold for investors?
The Motley Fool October 5, 2006 Rich Smith	Great Chemistry at Lab Corp UnitedHealth Group has canceled its lab-testing contract with Quest and named Lab Corp. as its new service provider. This is an interesting situation for investors.
The Motley Fool July 25, 2007 Ryan Fuhrmann	The Latest Procedure From Quest Diagnostics Quest Diagnostics took a hit earlier this year from the loss of a major contract, but the lab testing firm isn't down for the count.
The Motley Fool October 24, 2006 Ryan Fuhrmann	LabCorp's Positive Results The good times continue. After taking a major client from Quest Diagnostics, the company reports strong third-quarter earnings.
The Motley Fool February 8, 2007 Rich Duprey	Foolish Forecast: LabCorp Tests Positive The clinical lab-testing outfit is set to report its fourth-quarter 2006 earnings. Investors, here is what you can expect to see.
The Motley Fool April 27, 2007 Ryan Fuhrmann	LabCorp Tests Positive LabCorp is doing well focusing on managed care -- so far. Recent results were "outstanding by every measure" and could signal even better things to come. Investors, take note.
The Motley Fool April 20, 2007 Ryan Fuhrmann	Diagnosing Quest Diagnostics Quest should recover from a recent, painful contract loss. Shares trade for a reasonable 17.5 times earnings, and even lower multiple of free cash flow.
The Motley Fool March 12, 2007 Ryan Fuhrmann	Esoteric Results at Bio-Reference Labs Bio-Reference Labs is a small firm in the lab-testing field, but worth a look from investors.
The Motley Fool February 17, 2005 Rich Smith	LabCorp Tests Positive The results show strong bottom-line growth for the health-care test provider. Compared to the pricier Quest, it's at least a relative bargain price at which investors can own an interest in this essential piece of the health-care market.
The Motley Fool April 19, 2007 Ryan Fuhrmann	Quest Diagnostics Becomes Un-United: Fool by Numbers The lab-testing firm released first-quarter 2007 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool July 21, 2005 W.D. Crotty	The Lab Is Fab Laboratory Corporation of America produces more healthy results. Quest is a better value today based on earnings growth, but both companies are an excellent bet.
The Motley Fool June 11, 2007 Billy Fisher	Big Dollars in Diagnostic Deals CIGNA extends multi-year deals to a pair of powerhouses. The Quest agreement is a comfort to investors, who now know that Quest will continue to be a contracted provider for one of the nation's largest health insurers.
The Motley Fool September 6, 2007 Ryan Fuhrmann	Bio-Reference Labs Passes the Test Small-cap lab-testing firm Bio-Reference Labs third-quarter results beat analysts projections by a decent margin, again proving it can compete with the big boys in the highly competitive New York metro area.
The Motley Fool September 5, 2007 Ryan Fuhrmann	Foolish Forecast: A Test From BioReference Labs In advance of lab-testing firm BioReference Labs Q3 earnings report, analysts are predicting another quarter of double-digit earnings for the small but fast-growing regional company.
The Motley Fool October 20, 2005 Rich Smith	LabCorp: Boring Can Be Good The company is firmly on track toward this year's goal of $440 million to $465 million in free cash flow. Should the company hit even the low end of that guidance, it would be valued at under 16 times FCF, smack dab in between its projected growth rate and its return on equity.
The Motley Fool July 24, 2008 Brian Orelli	UnitedHealth Looking Healthier UnitedHealth Group isn't quite as sick as it appeared earlier this month, when it slashed yearly guidance by as much as $0.60 per share.
The Motley Fool February 13, 2009 Brian Orelli	Lynch Would Love This Company Double-digit revenue growth in this market is nothing to sneeze at, but that's what LabCorp has delivered.
The Motley Fool June 7, 2007 Ryan Fuhrmann	Big Gains for a Little Lab-Tester While bigger competitors stumble over each other, Bio-Reference keeps growing. This company may just be a welcome investment alternative as its two larger peers keep getting in each other's way.
The Motley Fool April 22, 2009 Brian Orelli	UnitedHealth Rocks; Its Stock Doesn't With all the good news floating around, why is UnitedHealth still trading at 7.3 times the middle of this year's guidance? Alas, there's still plenty of uncertainty hanging over the company.
The Motley Fool April 20, 2005 Rich Smith	LabCorp Hides Good News The company inexplicably hides its successful numbers from all but the most resourceful investors.
The Motley Fool March 31, 2011 David Williamson	Embarking on a Profitable Quest Quest Diagnostics has been busy, snapping up a pair of smaller players and seeing its share price recover to near 52-week highs. Let's take a look at what these acquisitions mean going forward.
The Motley Fool July 3, 2008 Brian Orelli	UnitedHealth Isn't Healthy On top of a $0.40-per-share cut in yearly guidance last quarter, the health insurer announces that it's slashing guidance by as much as another $0.60 per share.
The Motley Fool February 4, 2011 Brian Orelli	Glaxo Sold Quest Shares. Should You? Glaxo has somewhere else to spend the capital. Do you?
The Motley Fool March 9, 2007 Ryan Fuhrmann	Referencing Bio-Reference's Q1: Fool by Numbers The Northeastern clinical lab test provider released first-quarter 2007 results. Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
Managed Care April 2007 Scott Kober	Managed Care Seeks More from Clinical Laboratories Contracting advantage has sometimes been with the nationwide labs, but health plans are getting serious about price, service, and patient data.
The Motley Fool March 12, 2004 Alyce Lomax	Aetna's Picture of Health For the second time in very recent memory, Aetna (NYSE: AET) raised its guidance today, pushing its stock to a new 52-week high. The health insurance provider has suffered travails over the last several years, and investors apparently took the news as an added sign that things are on the mend.
The Motley Fool April 26, 2007 Ryan Fuhrmann	LabCorp Measures Up: Fool by Numbers The lab testing firm released results for the first quarter 2007: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool April 27, 2005 Tim Hanson	Quest for Value and Growth Quest Diagnostics, a consistent winner, could be good medicine for your portfolio.
The Motley Fool April 23, 2008 Morgan Housel	UnitedHealth: Bargain or Value Trap? A dismal start to 2008 sent the insurer's shares tumbling, and the news keeps getting worse and worse.
The Motley Fool May 8, 2006 Tom Taulli	Quest Software: Hugging Microsoft By expanding its products to the Microsoft line, the software company should see more growth. Investors, take note.
The Motley Fool June 6, 2007 Ryan Fuhrmann	Foolish Forecast: Bio-Reference Labs Nudges Competitors The clinical laboratory testing company is set to release it second-quarter earnings report. Investors, here is what you can expect to see.
The Motley Fool October 14, 2004 Rich Smith	UnitedHealth's Prognosis Is Good The health insurer beats some estimates and raises others.
The Motley Fool June 15, 2005 Bobby Shethia	A New Test for Quest The medical testing leader hopes to improve its steady performance via the rapidly growing gene-testing market. But sustained growth will require hefty capital expenditures. Investors, take note.
The Motley Fool April 18, 2006 Stephen D. Simpson	UnitedHealth Down, but Not Out There's nothing wrong with this company except for its stock price. Even with the year-to-date decline in the stock, it's still not at a level worth buying.
The Motley Fool June 28, 2007 Billy Fisher	A Strong Start for Big Health Care A look at how four blue-chip insurers have fared in the first half of 2007. Aetna... CIGNA... UnitedHealth... WellPoint...
The Motley Fool January 22, 2009 Brian Orelli	UnitedHealth Says Good Riddance to 2008 For 2009 the company is looking for earnings essentially flat compared to last year. That doesn't seem so bad, considering that it's expecting to lose as many as 1.5 million members as the unemployment rate grows.
The Motley Fool January 22, 2010 Brian Orelli	UnitedHealth: Beats Earnings, and Gets Beat Down? UnitedHealth was healthy last quarter, but on Wall Street, it's the future that counts.
The Motley Fool April 12, 2007 Rich Duprey	Foolish Forecast: Checking UnitedHealth's Vitals The health services provider will report its first-quarter 2007 financial results shortly. Investors, here is what you can expect to see.
The Motley Fool April 16, 2008 Ryan Fuhrmann	MEDTOX Fails the Test The Motley Fool - MEDTOX posted a weak quarter from a tough job market.
The Motley Fool May 28, 2009 Brian Orelli	When All Else Fails Save the customer money so they can give it to you.
The Motley Fool February 9, 2006 Stephen D. Simpson	Aexcellence From Aetna Low medical costs and good cash flow make this stock worth watching.
The Motley Fool January 27, 2009 Brian Orelli	Testing a Recession-Resistant Hypothesis Quest Diagnostic looks poised for growth even in bad times.
The Motley Fool October 22, 2007 Billy Fisher	An Unwavering Approach at UnitedHealth Group UnitedHealth Group repurchases $2 billion of shares during Q3. Their disciplined pricing approach has enabled the company to consistently improve operating margins.
The Motley Fool September 14, 2011 Frank Vinluan	Here's How New Roche Cancer Drug Zelboraf Benefits LabCorp A new Roche cancer drug expected to become a blockbuster could also end up being a boon for laboratory and diagnostics firm LabCorp.
The Motley Fool April 14, 2005 Stephen D. Simpson	UnitedHealth Keeps Growing Strong Can anything slow down this health insurance titan? Investors will probably come out OK even as growth slows down across the industry.
The Motley Fool December 9, 2011 Paul Chi	3 Europe-Proof Stocks for Your Portfolio These health-care stocks are Europe-proof.
The Motley Fool April 8, 2008 Colleen Paulson	Invest Where the Jobs Are Think about these growing sectors for your next investing opportunities.
The Motley Fool July 7, 2005 Stephen D. Simpson	UnitedHealth Swallows PacifiCare This high-performance HMO is getting bigger again, but taking on a bit of risk to do so. Investors, take note.
The Motley Fool July 19, 2006 Stephen D. Simpson	Is It OK to Like UnitedHealth Again? Smacked by an options scandal and fears of price competition, United Health got too cheap. Investors, take note.